Key Highlights

  • Third-quarter 2026 net loss was USD 64.6 million, or USD 4.52 per share.
  • Change in Fair Value of milestone Warrant rights Liability was USD 57.1 million.
  • General and administrative expenses were USD 5.8 million, against USD 1.2 million.
  • Cash and cash equivalents were USD 22.0 million as of September 30, 2026.

Azora Therapeutics (NASDAQ:AZR) reported a net loss of USD 64.6 million, or USD 4.52 per share, for the third quarter ended September 30, 2026, against an estimate of a loss of USD 0.34, with no Revenue reported. The company, formerly known as Adial Pharmaceuticals, changed its name effective October 29, 2026, and its common stock began trading on the Nasdaq under the new symbol.

Quarterly Financial Results

Research and development expenses were USD 1.8 million, against USD 0.5 million in the third quarter of 2025. General and administrative expenses increased approximately USD 4.5 million, or 363%, to USD 5.8 million from USD 1.2 million. Total operating expenses were USD 7.5 million, against USD 1.8 million, and loss from operations was USD 7.5 million, against USD 1.8 million.

The company recorded a USD 57.1 million loss from the change in fair value of its milestone warrant rights liability in the quarter, with no such item a year earlier. Interest income was USD 170 thousand, against USD 48 thousand, which the company attributed to additional interest income received during the quarter. Net loss for the quarter was USD 64.6 million.

Nine-Month Results and Cash

For the nine months ended September 30, 2026, total operating expenses were USD 61.6 million, which included a one-time acquired in-process Research and Development charge of USD 46.2 million. General and administrative expenses increased approximately USD 8.8 million, or 225%, to USD 12.7 million. Research and development expenses were USD 2.6 million, against USD 2.0 million. Other items for the nine months included a USD 48.8 million loss from the change in fair value of the milestone warrant rights liability, USD 2.1 million of financing expense allocated to that liability and a USD 6.1 million loss on extinguishment of Azora convertible promissory notes. Interest income for the nine months was USD 275 thousand, against USD 107 thousand.

The company reported net losses of approximately USD 118.6 million for the nine months ended September 30, 2026, inclusive of the USD 46.2 million write-off, against USD 8.0 million for the year ended December 31, 2025. Net cash used in Operating Activities for the nine months was USD 14.6 million, against USD 5.2 million. As of September 30, 2026, cash and cash equivalents were USD 22.0 million, against USD 5.9 million at December 31, 2025, and the accumulated Deficit was approximately USD 208.5 million.

Corporate Developments

The company acquired privately held Azora Therapeutics on June 11, 2026, and the acquired Business is now a wholly owned subsidiary. At its 2026 Annual Meeting of Stockholders held on September 17, 2026, stockholders approved an amendment to the certificate of incorporation to increase authorized common shares from 100,000,000 to 500,000,000, along with the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.

The filing also states that the company's forward-looking statements relate to future plans for acquisitions and changes to its business, management team and Board of Directors following the Acquisition of Azora.